

Cipla Launches India's Only Inhaled Insulin, Afrezza®

Mumbai, December 22, 2025: Cipla Limited (BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla") today announced the launch of Afrezza® (insulin human) Inhalation Powder in India. Cipla had obtained regulatory approval from Central Drugs Standard Control Organisation (CDSCO) late last year, for the exclusive distribution and marketing of Afrezza®, a rapid-acting orally inhaled insulin, which offers a needle-free, convenient alternative to injectable insulin therapy. The launch of this product in India is expected to benefit many of the 10 crore adults currently living with diabetes mellitus.

The insulin inhalation powder in Afrezza® is available in single use cartridges and is delivered via an inhaler device. The process of inhaling insulin is simple — selecting the appropriate dose cartridge, loading the cartridge in the inhaler device, inhaling the insulin from the device and removing the cartridge from the device. It is typically initiated with the largest meal of the day and can be intensified as needed. Afrezza®, which is created and manufactured by MannKind Corporation (MannKind) USA, dissolves rapidly upon oral inhalation and begins lowering blood glucose within approximately 12 minutes, closely mirroring the body's natural insulin response. By offering a needle-free, rapid-acting alternative to daily prandial injections, it is designed to support better adherence and enable quicker glycemic control for adults with both type 1 and type 2 diabetes mellitus. This differentiated delivery system also helps address the emotional and practical barriers that often lead patients to delay or discontinue insulin therapy, which is a need that leading healthcare experts continue to highlight as critical in strengthening diabetes care.

Commenting on the launch, **Achin Gupta, Global Chief Operating Officer**, Cipla Limited, said: "At Cipla, our purpose has always been simple – to make quality healthcare more accessible for every patient. The introduction of Afrezza® in India reflects that responsibility. This innovation not only simplifies insulin delivery but also eases many of the emotional and practical barriers patients face with daily insulin injections. With our reach and our deep commitment to patient well-being, we hope to support millions of Indians in managing their diabetes with greater confidence and comfort."

To address the emotional and behavioral barriers that often hinder insulin adherence, Cipla will also roll out a nationwide awareness initiative. The campaign will focus on overcoming fears around injections, complex treatment routines, and social stigma through empathetic storytelling and structured patient-support efforts. The initiative will run across digital platforms and on-ground engagements towards education, empowerment, and destigmatisation in diabetes care.

About Cipla:

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Sep'25), 2nd Largest in the pharma prescription market in South Africa

(IQVIA MAT Aug'25), and 4th largest by prescription in the US Gx (Repulses + MDI) products (IQVIA MAT Aug'25). For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

For queries, please contact:

Corporate Communications

Heena Kanal

E-Mail: CorpComm@cipla.com

Investor Relations

Diksha Maheshwari

E-Mail: Investor.Relations@cipla.com